StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Ocular Therapeutix's total debt was $72.80M at Jun 30, 2026. For fiscal 2025 it was $71.34M, up 4.1% from the year before. Over ten years it grew 16.7% a year on average. The highest annual figure on record is $71.34M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$71.34M+4.1%
FY2024Dec 31, 2024$68.51M+4.1%
FY2023Dec 31, 2023$65.79M+160.5%
FY2022Dec 31, 2022$25.26M+1.0%
FY2021Dec 31, 2021$25.00M+47.6%
FY2020Dec 31, 2020$16.94M-32.3%
FY2019Dec 31, 2019$25.01M+0.9%
FY2018Dec 31, 2018$24.79M+98.8%
FY2017Dec 31, 2017$12.47M-11.5%
FY2016Dec 31, 2016$14.09M-7.7%
FY2015Dec 31, 2015$15.27M+13.0%
FY2014Dec 31, 2014$13.51M+1975.4%
FY2013Dec 31, 2013$651.00K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$72.80M+4.1%
Q1 FY2026Mar 31, 2026$72.06M+4.1%
Q4 FY2025Dec 31, 2025$71.34M+4.1%
Q3 FY2025Sep 30, 2025$70.62M+4.1%
Q2 FY2025Jun 30, 2025$69.91M+4.1%
Q1 FY2025Mar 31, 2025$69.20M+4.1%
Q4 FY2024Dec 31, 2024$68.51M+4.1%
Q3 FY2024Sep 30, 2024$67.82M+4.1%
Q2 FY2024Jun 30, 2024$67.13M+188.1%
Q1 FY2024Mar 31, 2024$66.46M+162.5%
Q4 FY2023Dec 31, 2023$65.79M+160.5%
Q3 FY2023Sep 30, 2023$65.12M+158.5%
Q2 FY2023Jun 30, 2023$23.30M-7.3%
Q1 FY2023Mar 31, 2023$25.32M+1.0%
Q4 FY2022Dec 31, 2022$25.26M+1.0%
Q3 FY2022Sep 30, 2022$25.19M+1.0%
Q2 FY2022Jun 30, 2022$25.13M+1.0%
Q1 FY2022Mar 31, 2022$25.06M+68.1%
Q4 FY2021Dec 31, 2021$25.00M+47.6%
Q3 FY2021Sep 30, 2021$24.94M+31.5%
Q2 FY2021Jun 30, 2021$24.89M+18.7%
Q1 FY2021Mar 31, 2021$14.91M-35.2%
Q4 FY2020Dec 31, 2020$16.94M-32.3%
Q3 FY2020Sep 30, 2020$18.96M-24.0%
Q2 FY2020Jun 30, 2020$20.97M-15.8%
Q1 FY2020Mar 31, 2020$22.99M-7.5%
Q4 FY2019Dec 31, 2019$25.01M+0.9%
Q3 FY2019Sep 30, 2019$24.95M+209.1%
Q2 FY2019Jun 30, 2019$24.90M+160.8%
Q1 FY2019Mar 31, 2019$24.84M+125.6%
Q4 FY2018Dec 31, 2018$24.79M+98.8%
Q3 FY2018Sep 30, 2018$8.07M-42.0%
Q2 FY2018Jun 30, 2018$9.55M-37.9%
Q1 FY2018Mar 31, 2018$11.01M-34.5%
Q4 FY2017Dec 31, 2017$12.47M-11.5%
Q3 FY2017Sep 30, 2017$13.92M+18.2%
Q2 FY2017Jun 30, 2017$15.37M–
Q1 FY2017Mar 31, 2017$16.82M–
Q4 FY2016Dec 31, 2016$14.09M–
Q3 FY2016Sep 30, 2016$11.78M–

More Ocular Therapeutix figures

See a number that looks wrong?